Operator: Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Third Quarter 2025 ...

Genetix Biotherapeutics Inc. today announced that an analysis of recent patient experience data from the commercial implementation of LYFGENIAtm and ZYNTEGLOtm in the U.S. has been selected for oral ...

ISLAMABAD: A child and an adult were reportedly exposed to HIV last month here after infected blood and components were issued by the blood bank of Pakistan Institute of Medical Sciences due ...

This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 ...

Advancements in research and ongoing clinical trials related to HDFN prevention and treatment can change HDFN care for the better.

Platelets are small, disk-shaped cell fragments in the blood that are essential to stop bleeding and to initiate blood ...

Platelets are small, disc-shaped cell fragments in the blood that are essential to stop bleeding and to initiate blood ...

According to Precedence Research, the global immunohematology market size will grow from USD 2.86 billion in 2025 to nearly ...

Plasma C-reactive protein (CRP) is widely used as a biomarker for bacterial infection, but its biological function remains ...

Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...